This review describes the history of Ebola monoclonal antibody (mAb) development leading
up to the recent severe Ebola outbreak in West Africa. The Ebola virus has presented …

Ebola virus disease (EVD) remains among the biggest public health threats in Africa, even
though recently a vaccine was approved for human use. However, in outbreak situations …

Introduction: To date, the management of patients with suspected or confirmed Ebolavirus
disease (EVD) depends on quarantine, symptomatic management and supportive care, as …

Highlights•Antibody therapy has historically been successful against a wide variety of
pathogens.•Only recently have antibodies shown efficacy in non-human primates against …

Ebola viruses can cause severe hemorrhagic fever in humans and nonhuman primates with
fatality rates up to 90%, and are identified as biosafety level 4 pathogens and CDC Category …

Highlights•mAbs mixture targeting independent epitopes are better therapeutics.•Optimizing
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …

The ebolavirus immunotherapeutics field has replaced previous perceptions of antibody
inadequacy with a new abundance of monoclonals exhibiting post exposure efficacy. Now …

Ebola virus disease in humans is highly lethal, with case fatality rates ranging from 25 to
90%. There is no licensed treatment or vaccine against the virus, underscoring the need for …

Ebola virus causes lethal hemorrhagic fever in humans and nonhuman primates, but no
effective antiviral compounds are available for the treatment of this infection. The surface …

Successful Ebola treatments promise to tame outbreak | Science news careers commentary
Journals Science Science brought to you byGoogle Indexer Log in science science advances …